@entity1205 (Taxotere), alone or in combination with other anticancer agents, has proven efficacy in the first- and second-line treatment of metastatic @entity0 . This phase II study investigated the efficacy and tolerability of @entity1205 as neoadjuvant chemotherapy in @entity1 with stage II-III primary operable @entity0 . @entity1 (n=88) were treated with six cycles of @entity1205 at 100 mg m(-2) every 21 days, followed by definitive surgery and radiotherapy. After six cycles of @entity1205 , the overall clinical response rate was 68.4% (CI 95%: 58.1-78.7%), including 19.0% complete remissions. Breast conservation was achieved in 72.4% of @entity1 . A high pathological complete response (pCR) rate in breast was confirmed in 15 @entity1 (19.8% (CI 95%: 10.8-28.8%)) on Chevallier's classification restricted to breast and in 27 @entity1 (35.5% (CI 95%: 24.7-46.3%)) on Sataloff's classification. After a median follow-up of 30.8 months, 19 recurrences were documented with a median time to first recurrence of 17.3 months. @entity1 with @entity5 had more recurrences than @entity1 with @entity5 (P=0.02). The principal @entity137 of @entity1205 is myelosuppression and 70.5% of @entity1 developed grade III or IV @entity1398 with 13.6% developing @entity1398 . There was no case of severe @entity1370 , @entity882 or any other serious adverse events. In conclusion, neoadjuvant @entity1205 induces a high pCR and breast-conservation rate. @entity1205 monotherapy is a highly effective regimen that merits formal comparison with currently used combination regimens in a randomised phase III study.

Neoadjuvant XXXX for operable @entity0 induces a high pathological response and breast-conservation rate.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage II tumours', 'stage III tumours'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'neutropenic sepsis'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiac toxicity'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel', 'docetaxel']
@entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']
